Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy

Thorax

Volumn 68, Issue 10, 2013, Pages 955-961

  Singanayagam, Aran ^a   Manalan, Kavina ^a   Sridhar, Saranya ^a   Molyneaux, Philip L ^a   Connell, David W ^a   George, Peter M ^a   Kindelerer, Anne ^a   Seneviratne, Suranjith ^a   Lalvani, Ajit ^a   Wickremasinghe, Melissa ^a   Kon, Onn Min ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; RIFAMPICIN; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CHEMOPROPHYLAXIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; TUBERCULIN TEST; UNSPECIFIED SIDE EFFECT;

TUBERCULOSIS;

ADULT; AGED; ANTITUBERCULAR AGENTS; CHEMOPREVENTION; CHRONIC DISEASE; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK ASSESSMENT; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884556119     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203436     Document Type: Article

References (35)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
2. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-206.
3. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85. (Pubitemid 43736578)
4. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. ArthritisRheum 2005; 52: 1766-72. (Pubitemid 40852885)
5. Ormerod LP, Milburn HJ, Gillspie S, et al. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-5. (Pubitemid 41475202)
6. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003; 62: 791. (Pubitemid 36886422)
7. American Thoracic Society and Centers for disease control and prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161(4 Pt 2):S221-47.
8. Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010; 49: 2217-19.
9. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha- California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53: 683-6.
10. National Institute for Clinical Excellence (NICE). Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control, 2011. http://guidance.nice.org.uk/CG117/NICEGuidance/pdf/English (accessed 13 Aug 2013).
11. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002; 347: 1860-6. (Pubitemid 35417778)
12. Behar SM, Shin DS, Maier A, et al. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol 2009; 36: 546-51.
13. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008; 35: 776-81. (Pubitemid 351747116)
14. Martin J, Walsh C, Gibbs A, et al. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010; 69: 181-5.
15. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008; 27: 907-13.
16. Kleinert S, Kurzai O, Elias J, et al. Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2010; 69: 782-4.
17. Matulis G, Juni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008; 67: 84-90.
18. Martyn-Simmons CL, Mee JB, Kirkham BW, et al. Evaluating the use of the interferon-gamma response to Mycobacterium tuberculosis specific antigens in patients with psoriasis prior to anti-tumour necrosis factor alpha therapy: a prospective head-to-head cross sectional study. Br J Dermatol 2012; 168: 1012-8.
19. Pareek M, Bond M, Shorey J, et al. Community-based evaluation of immigrant tuberculosis screening using interferon gamma release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013; 68: 230-9.
20. Public Health Agency of Canada. Canadian tuberculosis standards. Ottawa 2007 [cited 2012 November]; http://www.phave-aspc.gc.ca/tbpc-lath/pubs/pdf/ tbstand07- e.pdf%5D.
21. Pedrazzoli D, Fulton N, Anderson L, et al. Tuberculosis section, Health Protection Services, HPA. Tuberculosis in the UK: 2012 report. www.hpa.org.uk/Publications/InfectiousDseases/Tuberculosis/ 1206TBintheUK2012report (accessed 13 Aug 2013).
22. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1. (Pubitemid 41206259)
23. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56: 230-8.
24. Cobelens FG, Menzies D, Farhat M. False-positive tuberculin reactions due to non-tuberculous mycobacterial infections. Int J Tuberc Lung Dis 2007; 11: 934-5. (Pubitemid 47227632)
25. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-204. (Pubitemid 44713473)
26. Comstock GW, Livesay VT, Woolpert SF. Evaluation of BCG vaccination among Puerto Rican children. Am J Public Health 1974; 64: 283-91.
27. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010; 137: 952-68.
28. Mulder C, van Deutekom H, Huisman EM, et al. Role of the QuantiFERON(R)-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection. Eur Respir J 2012; 40: 1443-9.
29. Kim YJ, Kim SI, Kim YR, et al. Predictive value of interferon-gamma ELISPOT assay in HIV 1-infected patients in an intermediate tuberculosis-endemic area. AIDS Res Hum Retroviruses 2012; 28: 1038-43.
30. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008; 8: 147-52.
31. Redelman-Sidi G, Sepkowitz KA. Interferon gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med Published Online First: 21 Dec 2012. PMID: 23262514.
32. Smith R, Cattamanchi A, Steingart KR, et al. Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011; 23: 377-84.
33. Singanayagam A, Sridhar S, Dhariwal J, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med 2012; 185: 653-9.
34. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-71.
35. Dhasmana DJ, Nash J, Bradley JC, et al. TB screening and anti-TNFalpha treatment. Thorax 2006; 61: 641.